Complement resistance of human carcinoma cells depends on membrane regulatory proteins, protein kinases and sialic acid

Clinical and Experimental Immunology

Volumn 131, Issue 2, 2003, Pages 254-263

  Donin, N ^a   Jurianz, K ^b   Ziporen, L ^a   Schultz, S ^b   Kirschfink, M ^b   Fishelson, Zvi ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CD59; Complement resistance; Regulators; Sialic acid; Tumour immunology

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CD59 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; DECAY ACCELERATING FACTOR; MEMBRANE COFACTOR PROTEIN; MEMBRANE COMPLEMENT REGULATORY PROTEIN; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; POLYCLONAL ANTIBODY; PROTEIN KINASE; PROTEIN KINASE C; REGULATOR PROTEIN; SIALIC ACID; SIALIDASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; COMPLEMENT SYSTEM; CYTOLYSIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR IMMUNOLOGY;

ANTIGENS, CD55; ANTIGENS, CD59; COMPLEMENT INACTIVATOR PROTEINS; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNE TOLERANCE; MALE; NEOPLASMS; PROTEIN KINASES; SIALIC ACIDS; TUMOR CELLS, CULTURED;

EID: 0037316424     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2003.02066.x     Document Type: Article

References (61)

1. Green MC, Murray JL, Hortobagyi GN. Monoclonal antibody therapy for solid tumors. Cancer Treat Rev 2000; 26:269-86.
2. Vose JM. Antibody-targeted therapy for low-grade lymphoma. Semin Hematol 1999; 36:15-20.
3. Jurianz K, Ziegler S, Garcia-Schuler H et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999; 36:929-39.
4. Hourcade D, Liszewski MK, Krych-Goldberg M et al. Functional domains, structural variations and pathogen interactions of MCP, DAF and CR1. Immunopharmacology 2000; 49:103-16.
5. Davies A, Lachmann PJ. Membrane defence against complement lysis, the structure and biological properties of CD59. Immunol Res 1993; 12:258-75.
6. Meri S, Morgan BP, Davies A et al. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology 1990; 71:1-9.
7. Niehans GA, Cherwitz DL, Staley NA et al. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996; 149:129-42.
8. Simpson KL, Jones A, Norman S et al. Expression of the complement regulatory proteins decay accelerating factor (DAF, CD55), membrane cofactor protein (MCP, CD46) and CD59 in the normal human uterine cervix and in premalignant and malignant cervical disease. Am J Pathol 1997; 151:1455-67.
9. Varsano S, Rashkovsky L, Shapiro H et al. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism (s) of resistance. Clin Exp Immunol 1998; 113:173-82.
10. Li L, Spendlove I, Morgan J et al. CD55 is over-expressed in the tumour environment. Br J Cancer 2001; 84:80-6.
11. Junnikkala S, Jokiranta TS, Friese MA et al. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J Immunol 2000; 164:6075-81.
12. Charriaut-Marlangue C, Barel M, Frade R. Identification of P-57, a serine proteinase, from human erythrocyte membranes, which cleaves both chains of human third component (C3) of complement. Biochem Biophys Res Commun 1986; 140:1113-20.
13. Ollert MW, Frade R, Fiandino A et al. C3-cleaving membrane proteinase. A new complement regulatory protein of human melanoma cells. J Immunol 1990; 144:3862-7.
14. Lauf PK. Immunological and physiological characteristics of the rapid immune hemolysis of neuraminidase-treated sheep red cells produced by fresh guinea pig serum. J Exp Med 1975; 142:974-88.
15. Jacobsen F. Increase of the in vitro complement-dependent cytotoxicity against autologous invasive human bladder tumor cells by neuraminidase treatment. Acta Pathol Microbiol Immunol Scand 1982; 90:187-92.
16. Fishelson Z, Kopf E, Paas Y et al. Protein phosphorylation as a mechanism of resistance against complement damage. Prog Immunol 1989; 7:205-8.
17. Kraus S, Fishelson Z. Cell desensitization by sublytic C5b-9 complexes and calcium ionophores depends on activation of protein kinase C. Eur J Immunol 2000; 30:1272-80.
18. Kraus S, Seger R, Fishelson Z. Involvement of the ERK mitogen-activated protein kinase in cell resistance to complement-mediated lysis. Clin Exp Immunol 2001; 123:366-74.
19. Ohanian SH, Schlager SI. Humoral immune killing of nucleated cells: mechanisms of complement-mediated attack and target cell defense. Crit Rev Immunol 1981; 1:165-209.
20. Carney DF, Koski CL, Shin ML. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J Immunol 1985; 134:1804-9.
21. Morgan BP, Dankert JR, Esser AF. Recovery of human neutrophils from complement attack: removal of the membrane attack complex by endocytosis and exocytosis. J Immunol 1987; 138:246-53.
22. Reiter Y, Ciobotariu A, Jones J et al. Complement membrane attack complex, perforin, and bacterial exotoxins induce in K562 cells calcium-dependent cross-protection from lysis. J Immunol 1995; 155:2203-10.
23. Reiter Y, Ciobotariu A, Fishelson Z. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 1992; 22:1207-13.
24. Reiter Y, Fishelson Z. Complement membrane attack complexes induce in human leukemic cells rapid expression of large proteins (L-CIP). Mol Immunol 1992; 29:771-81.
25. Brodbeck WG, Mold C, Atkinson JP et al. Cooperation between decay-accelerating factor and membrane cofactor protein in protecting cells from autologous complement attack. J Immunol 2000; 165:3999-4006.
26. Chen S, Caragine T, Cheung NK et al. CD59 expressed on a tumor cell surface modulates decay-accelerating factor expression and enhances tumor growth in a rat model of human neuroblastoma. Cancer Res 2000; 60:3013-8.
27. Jurianz K, Ziegler S, Donin N et al. K562 erythroleukemic cells are equipped with multiple mechanisms of resistance to lysis by complement. Int J Cancer 2001; 93:848-54.
28. Gotze O, Muller-Eberhard HJ. The C3-activator system: an alternate pathway of complement activation. J Exp Med 1971; 134:90s-108s.
29. Blomberg K, Hautala R, Lovgren J et al. Time-resolved fluorometric assay for natural killer activity using target cells labelled with a fluorescence enhancing ligand. J Immunol Meth 1996; 193:199-206.
30. Jurianz K, Maslak S, Garcia-Schuler H et al. Neutralization of complement regulatory proteins augments lysis of breast carcinoma cells targeted with rhumAb anti-HER2. Immunopharmacology 1999; 42:209-18.
31. Toullec D, Pianetti P, Coste H et al. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem 1991; 266:15771-81.
32. Combest WL, Bloom TJ, Gilbert LI. Polyamines differentially inhibit cyclic AMP-dependent protein kinase-mediated phosphorylation in the brain of the tobacco hornworm, Manduca sexta. J Neurochem 1988; 51:1581-91.
33. Chijiwa T, Mishima A, Hagiwara M et al. Inhibition of forskolin-induced neurite outgrowth and protein phosphorylation by a newly synthesized selective inhibitor of cyclic AMP-dependent protein kinase, N-[2-(p-bromocinnamylamino)ethyl]-5-isoquinolinesulfonamide (H-89), of PC12D pheochromocytoma cells. J Biol Chem 1990; 265:5267-72.
34. Collard CD, Vakeva A, Morrissey MA et al. Complement activation after oxidative stress. Role of the lectin complement pathway. Am J Pathol 2000; 156:1549-56.
35. Kobayashi E, Nakano H, Morimoto M et al. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun 1989; 159:548-53.
36. Seya T, Kojima A, Hara T et al. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55). Immunobiology 1991; 183:115-24.
37. Marchbank KJ, Morgan BP, van den Berg CW. Regulation of CD59 expression on K562 cells: effects of phorbol myristate acetate, cross-linking antibody and non-lethal complement attack. Immunology 1995; 85:146-52.
38. Goslings WR, Blom DJ, de Waard-Siebinga I et al. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas. Invest Ophthalmol Vis Sci 1996; 37:1884-91.
39. Bjorge L, Hakulinen J, Wahlstrom T et al. Complement-regulatory proteins in ovarian malignancies. Int J Cancer 1997; 70:14-25.
40. Koretz K, Bruderlein S, Henne C et al. Expression of CD59, a complement regulator protein and a second ligand of the CD2 molecule, and CD46 in normal and neoplastic colorectal epithelium. Br J Cancer 1993; 68:926-31.
41. Hakulinen J, Meri S. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer cells. Laboratory Invest 1994; 71:820-7.
42. Jarvis GA, Li J, Hakulinen J et al. Expression and function of the complement membrane attack complex inhibitor protectin (CD59) in human prostate cancer. Int J Cancer 1997; 71:1049-55.
43. Frey A, Giannasca KT, Weltzin R et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996; 184:1045-59.
44. Brasoveanu LI, Fonsatti E, Visintin A et al. Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity. J Clin Invest 1997; 100:1248-55.
45. Blok VT, Daha MR, Tijsma OM et al. A possible role of CD46 for the protection in vivo of human renal tumor cells from complement-mediated damage. Laboratory Invest 2000; 80:335-44.
46. Pangburn MK, Muller-Eberhard HJ. Complement C3 convertase, cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells. Proc Natl Acad Sci USA 1978; 75:2416-20.
47. Ray PK, Sundaram K. Cytolysis of neuraminidase-treated autochthonous lymphoid cells by autologous serum. Clin Exp Immunol 1975; 19:529-32.
48. Turianskyj FH, Gyenes L. The effect of neuraminidase on the sensitivity of tumor cells toward lysis by antibody and complement or by sensitized lymphocytes. Transplantation 1976; 22:24-30.
49. Kipnis TL, David JR, Alper CA et al. Enzymatic treatment transforms trypomastigotes of Trypanosoma cruzi into activators of alternative complement pathway and potentiates their uptake by macrophages. Proc Natl Acad Sci USA 1981; 78:602-5.
50. Jarvis GA, Vedros NA. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect Immun 1987; 55:174-80.
51. Ram S, Sharma AK, Simpson SD et al. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J Exp Med 1998; 187:743-52.
52. Kazatchkine MD, Fearon DT, Austen KF. Human alternative complement pathway, membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol 1979; 122:75-81.
53. Meri S, Pangburn MK. Discrimination between activators and nonactivators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc Natl Acad Sci USA 1990; 87:3982-6.
54. Reiter Y, Fishelson Z. Killing of human tumor cells by antibody C3b conjugates and human complement. Targeted Diagn Ther 1989; 2:119-35.
55. Morgan BP, Campbell AK. The recovery of human polymorphonuclear leucocytes from sublytic complement attack is mediated by changes in intracellular free calcium. Biochem J 1985; 231:205-8.
56. Bjorge L, Jensen TS, Matre R. Characterisation of the complement-regulatory proteins decay-accelerating factor (DAF, CD55) and membrane cofactor protein (MCP, CD46) on a human colonic adenocarcinoma cell line. Cancer Immunol Immunother 1996; 42:185-92.
57. Hindmarsh EJ, Marks RM. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 1998; 28:1052-62.
58. Marchbank KJ, van den Berg CW, Morgan BP. Mechanisms of complement resistance induced by non-lethal complement attack and by growth arrest. Immunology 1997; 90:647-53.
59. Fishelson Z, Hochman I, Greene LE et al. Contribution of heat shock proteins to cell protection from complement-mediated lysis. Int Immunol 2001; 13:983-91.
60. Frade R. Structure and functions of proteases which cleave human C3 and are expressed on normal or tumor human cells: some are involved in tumorigenic and metastatic properties of human melanoma cells. Immunopharmacology 1999; 42:39-45.
61. Paas Y, Bohana-Kashtan O, Fishelson Z. Phosphorylation of the complement component, C9, by an ecto-protein kinase of human leukemic cells. Immunopharmacology 1999; 42:175-85.